Epstein-barr virus (ebv) infection
Drug research and approvals for epstein-barr virus (ebv) infection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 161 studies of epstein-barr virus (ebv) infection are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 161
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 161 recruiting on ClinicalTrials.gov ↗- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic…NCT07758673 · Phase 1 · City of Hope Medical Center · starts Apr 17, 2027
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNCT07069699 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Jan 11, 2027
- mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young AdultsNCT07557602 · Phase 1 · Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company · starts Nov 16, 2026
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With…NCT07648264 · Phase 3 · CSL Behring · starts Sep 15, 2026
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)NCT07476729 · Phase 3 · Charite University, Berlin, Germany · starts Sep 1, 2026
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaNCT07532525 · Phase 1 · University of Michigan Rogel Cancer Center · starts Aug 26, 2026
- A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)NCT06789159 · Phase 1 · Pierluigi Porcu · starts Aug 21, 2026
- Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney…NCT07368153 · Phase 2 · University Hospital, Basel, Switzerland · starts Aug 20, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 21, 2024 | A randomized phase II study of nivolumab versus nivolumab and bms-986016 (relatlimab) as maintenance treatment after first-line treatment with…RELATLIMAB (BMS-986016) / NIVOLUMAB (BMS-936558) | NRG ONCOLOGY | Pending |
| Dec 2, 2021 | An open-label, multicenter phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced epstein-barr virus-positive (ebv+) solid tumors and in…NANATINOSTAT (VRX-3996)/ VALGANCICLOVIR/ PEMBROLIZUMAB | VIRACTA THERAPEUTICS INC. | Closed |
| Jun 23, 2021 | An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with epstein-barr virus-positive (ebv+) relapsed/refractory…NANATINOSTAT/ VALGANCICLOVIR/ GANCICLOVIR | VIRACTA THERAPEUTICS INC. | Closed |
| Apr 16, 2020 | A phase I/ii open-label study of the safety and efficacy of epstein-barr virus specific t-cell lines for the treatment of ebv infection or ebv-related…EBV-TCL-01 | CHU SAINTE JUSTINE | Pending |
| Sep 3, 2015 | A phase I/ii open-label study of the safety and efficacy of epstein-barr virus specific t-cell lines for the treatment of ebv infection or ebv-related…ANTI-EBV T-CELL LINES | HOPITAL MAISONNEUVE ROSEMONT | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 24, 2021 | nanatinostat and valganciclovirTreatment of Epstein Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS) | Epirare Therapeutics | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Dec 16, 2022 | Ebvallotabelecleucel · orphan | Pierre Fabre Medicament | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA